240 related articles for article (PubMed ID: 20100002)
1. Pim kinase inhibitors: a survey of the patent literature.
Morwick T
Expert Opin Ther Pat; 2010 Feb; 20(2):193-212. PubMed ID: 20100002
[TBL] [Abstract][Full Text] [Related]
2. Small molecule inhibitors of PIM1 kinase: July 2009 to February 2013 patent update.
Arunesh GM; Shanthi E; Krishna MH; Sooriya Kumar J; Viswanadhan VN
Expert Opin Ther Pat; 2014 Jan; 24(1):5-17. PubMed ID: 24131033
[TBL] [Abstract][Full Text] [Related]
3. The oncogenic PIM kinase family regulates drug resistance through multiple mechanisms.
Isaac M; Siu A; Jongstra J
Drug Resist Updat; 2011; 14(4-5):203-11. PubMed ID: 21601509
[TBL] [Abstract][Full Text] [Related]
4. Cyclin-dependent kinase inhibitors: a survey of recent patent literature.
Galons H; Oumata N; Meijer L
Expert Opin Ther Pat; 2010 Mar; 20(3):377-404. PubMed ID: 20180621
[TBL] [Abstract][Full Text] [Related]
5. Use of regulators and inhibitors of Pim-1, a serine/threonine kinase, for tumour therapy (review).
Liang C; Li YY
Mol Med Rep; 2014 Jun; 9(6):2051-60. PubMed ID: 24737044
[TBL] [Abstract][Full Text] [Related]
6. Small molecule c-Met kinase inhibitors: a review of recent patents.
Porter J
Expert Opin Ther Pat; 2010 Feb; 20(2):159-77. PubMed ID: 20100000
[TBL] [Abstract][Full Text] [Related]
7. Novel potent dual inhibitors of CK2 and Pim kinases with antiproliferative activity against cancer cells.
Pierre F; Regan CF; Chevrel MC; Siddiqui-Jain A; Macalino D; Streiner N; Drygin D; Haddach M; O'Brien SE; Rice WG; Ryckman DM
Bioorg Med Chem Lett; 2012 May; 22(9):3327-31. PubMed ID: 22460033
[TBL] [Abstract][Full Text] [Related]
8. Potential use of selective and nonselective Pim kinase inhibitors for cancer therapy.
Drygin D; Haddach M; Pierre F; Ryckman DM
J Med Chem; 2012 Oct; 55(19):8199-208. PubMed ID: 22924342
[No Abstract] [Full Text] [Related]
9. Structure-based design of 3-aryl-6-amino-triazolo[4,3-b]pyridazine inhibitors of Pim-1 kinase.
Grey R; Pierce AC; Bemis GW; Jacobs MD; Moody CS; Jajoo R; Mohal N; Green J
Bioorg Med Chem Lett; 2009 Jun; 19(11):3019-22. PubMed ID: 19414255
[TBL] [Abstract][Full Text] [Related]
10. 7-(4H-1,2,4-Triazol-3-yl)benzo[c][2,6]naphthyridines: a novel class of Pim kinase inhibitors with potent cell antiproliferative activity.
Pierre F; Stefan E; Nédellec AS; Chevrel MC; Regan CF; Siddiqui-Jain A; Macalino D; Streiner N; Drygin D; Haddach M; O'Brien SE; Anderes K; Ryckman DM
Bioorg Med Chem Lett; 2011 Nov; 21(22):6687-92. PubMed ID: 21982499
[TBL] [Abstract][Full Text] [Related]
11. Recent patents in the discovery of small molecule inhibitors of JAK3.
Wilson LJ
Expert Opin Ther Pat; 2010 May; 20(5):609-23. PubMed ID: 20402545
[TBL] [Abstract][Full Text] [Related]
12. Hit to lead account of the discovery of a new class of inhibitors of Pim kinases and crystallographic studies revealing an unusual kinase binding mode.
Qian K; Wang L; Cywin CL; Farmer BT; Hickey E; Homon C; Jakes S; Kashem MA; Lee G; Leonard S; Li J; Magboo R; Mao W; Pack E; Peng C; Prokopowicz A; Welzel M; Wolak J; Morwick T
J Med Chem; 2009 Apr; 52(7):1814-27. PubMed ID: 19256503
[TBL] [Abstract][Full Text] [Related]
13. Hit to lead evaluation of 1,2,3-triazolo[4,5-b]pyridines as PIM kinase inhibitors.
Pastor J; Oyarzabal J; Saluste G; Alvarez RM; Rivero V; Ramos F; Cendón E; Blanco-Aparicio C; Ajenjo N; Cebriá A; Albarrán MI; Cebrián D; Corrionero A; Fominaya J; Montoya G; Mazzorana M
Bioorg Med Chem Lett; 2012 Feb; 22(4):1591-7. PubMed ID: 22266039
[TBL] [Abstract][Full Text] [Related]
14. Structural analysis identifies imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity.
Pogacic V; Bullock AN; Fedorov O; Filippakopoulos P; Gasser C; Biondi A; Meyer-Monard S; Knapp S; Schwaller J
Cancer Res; 2007 Jul; 67(14):6916-24. PubMed ID: 17638903
[TBL] [Abstract][Full Text] [Related]
15. Platelet-derived growth factor receptor tyrosine kinase inhibitors: a review of the recent patent literature.
Dai Y
Expert Opin Ther Pat; 2010 Jul; 20(7):885-97. PubMed ID: 20509775
[TBL] [Abstract][Full Text] [Related]
16. The Pim kinases: new targets for drug development.
Swords R; Kelly K; Carew J; Nawrocki S; Mahalingam D; Sarantopoulos J; Bearss D; Giles F
Curr Drug Targets; 2011 Dec; 12(14):2059-66. PubMed ID: 21777193
[TBL] [Abstract][Full Text] [Related]
17. Pim 1 kinase inhibitor ETP-45299 suppresses cellular proliferation and synergizes with PI3K inhibition.
Blanco-Aparicio C; Collazo AM; Oyarzabal J; Leal JF; Albarán MI; Lima FR; Pequeño B; Ajenjo N; Becerra M; Alfonso P; Reymundo MI; Palacios I; Mateos G; Quiñones H; Corrionero A; Carnero A; Pevarello P; Lopez AR; Fominaya J; Pastor J; Bischoff JR
Cancer Lett; 2011 Jan; 300(2):145-53. PubMed ID: 21051136
[TBL] [Abstract][Full Text] [Related]
18. New patented histone deacetylase inhibitors.
Wang H; Dymock BW
Expert Opin Ther Pat; 2009 Dec; 19(12):1727-57. PubMed ID: 19939190
[TBL] [Abstract][Full Text] [Related]
19. Discovery of 3H-benzo[4,5]thieno[3,2-d]pyrimidin-4-ones as potent, highly selective, and orally bioavailable inhibitors of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM) kinases.
Tao ZF; Hasvold LA; Leverson JD; Han EK; Guan R; Johnson EF; Stoll VS; Stewart KD; Stamper G; Soni N; Bouska JJ; Luo Y; Sowin TJ; Lin NH; Giranda VS; Rosenberg SH; Penning TD
J Med Chem; 2009 Nov; 52(21):6621-36. PubMed ID: 19842661
[TBL] [Abstract][Full Text] [Related]
20. [The Pim family of protein kinases: structure, functions and roles in hematopoietic malignancies].
Zhukova IuN; Alekseeva MG; Zakharevich NV; Shtil' AA; Danilenko VN
Mol Biol (Mosk); 2011; 45(5):755-64. PubMed ID: 22393773
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
